Novo Nordisk

Novo Nordisk, a major pharmaceutical company, is currently newsworthy due to several factors surrounding its blockbuster drug semaglutide (Ozempic, Wegovy). The patent for semaglutide recently expired in key markets like India and China, opening the door for generic drug manufacturers and increased competition. This is particularly significant in China, where the weight-loss drug market is projected to reach $14 billion by 2030. Simultaneously, Novo Nordisk faces increasing competition from companies like Eli Lilly, which has received FDA approval for a new weight-loss pill, potentially challenging Novo Nordisk's injectable dominance. Furthermore, the company's chairman, Lars Rebien Sorensen, faces scrutiny from shareholders regarding the company's direction and performance. The rise in popularity of weight-loss drugs has also led to concerns about misuse, particularly in countries like India, where they are being marketed to brides seeking rapid weight loss before their weddings. These developments highlight Novo Nordisk's pivotal position in a rapidly evolving and increasingly competitive market.